Last reviewed · How we verify
NCT05984667: C-SMART
C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors
trial testing C-SMART in Glioma, Mixed in 32 participants. Completed in 23 July 2025.
23 July 2025
Quick facts
| Lead sponsor | Virginia Commonwealth University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 32 |
| Start date | 15 September 2023 |
| Primary completion | 23 July 2025 |
| Estimated completion | 23 July 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- C-SMART
Conditions studied
- Glioma, Mixed — all drugs for Glioma, Mixed →
- Mild Neurocognitive Disorder — all drugs for Mild Neurocognitive Disorder →
- Brain Tumor — all drugs for Brain Tumor →
Sponsor
Virginia Commonwealth University
Who can join
18 and older, any sex, with Glioma, Mixed or Mild Neurocognitive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of Phase Ib Trial is to determine the feasibility and acceptability of telehealth C-SMART for patients with primary brain tumor and mild neurocognitive deficits (N=18) and their caregivers (N=14) A subset (n=3) of participants will undergo rs-fMRI both pre- and post-C-SMART to test feasibility of advanced functional imaging in this population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05984667
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of C-SMART
Trials testing the same drug.
- NCT07224503 — C-SMART vs BE Well for Patients With Brain Tumors · NA · recruiting
Other recruiting trials for Glioma, Mixed
Currently open trials in the same condition.
- NCT04461938 — Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3) · NA · active not recruiting
Other Virginia Commonwealth University trials
Trials by the same sponsor.
- NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
- NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
- NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
- NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05984667 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
- Last refreshed: 20 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05984667.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing